ES2688786T3 - Nuevo uso - Google Patents

Nuevo uso Download PDF

Info

Publication number
ES2688786T3
ES2688786T3 ES10714956.9T ES10714956T ES2688786T3 ES 2688786 T3 ES2688786 T3 ES 2688786T3 ES 10714956 T ES10714956 T ES 10714956T ES 2688786 T3 ES2688786 T3 ES 2688786T3
Authority
ES
Spain
Prior art keywords
gal
cells
gos
tnf
mip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10714956.9T
Other languages
English (en)
Spanish (es)
Inventor
Georgios Tzortzis
Jelena Vulevic
Francesco Attanasio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clasado Inc
Original Assignee
Clasado Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40774842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2688786(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Clasado Inc filed Critical Clasado Inc
Application granted granted Critical
Publication of ES2688786T3 publication Critical patent/ES2688786T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
ES10714956.9T 2009-04-23 2010-04-23 Nuevo uso Active ES2688786T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0906983 2009-04-23
GBGB0906983.2A GB0906983D0 (en) 2009-04-23 2009-04-23 Novel use
GB0920784 2009-11-27
GBGB0920784.6A GB0920784D0 (en) 2009-04-23 2009-11-27 Novel use
PCT/GB2010/050659 WO2010122344A1 (en) 2009-04-23 2010-04-23 Novel use

Publications (1)

Publication Number Publication Date
ES2688786T3 true ES2688786T3 (es) 2018-11-06

Family

ID=40774842

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10714956.9T Active ES2688786T3 (es) 2009-04-23 2010-04-23 Nuevo uso

Country Status (25)

Country Link
US (1) US20120058972A1 (enExample)
EP (1) EP2421541B1 (enExample)
JP (1) JP2012524770A (enExample)
KR (1) KR20110138416A (enExample)
CN (1) CN102427818A (enExample)
AU (1) AU2010240642B2 (enExample)
BR (1) BRPI1015091A2 (enExample)
CA (1) CA2759442C (enExample)
CY (1) CY1120597T1 (enExample)
DK (1) DK2421541T3 (enExample)
ES (1) ES2688786T3 (enExample)
GB (3) GB0906983D0 (enExample)
HU (1) HUE040451T2 (enExample)
IL (1) IL215855A0 (enExample)
MX (1) MX341308B (enExample)
MY (1) MY151104A (enExample)
NZ (1) NZ595969A (enExample)
PL (1) PL2421541T3 (enExample)
PT (1) PT2421541T (enExample)
RU (1) RU2530567C2 (enExample)
SG (1) SG175313A1 (enExample)
TR (1) TR201810868T4 (enExample)
UA (1) UA106491C2 (enExample)
WO (1) WO2010122344A1 (enExample)
ZA (1) ZA201107821B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2492559B (en) * 2011-07-05 2018-07-25 Clasado Inc Composition and method for preventing or reducing the risk of developing a syndrome
BR112014001472A2 (pt) 2011-07-22 2017-02-21 Abbott Lab galactooligossacarídeos para prevenir lesões e / ou promover a cicatrização do trato gastrointestinal
CN103716787B (zh) 2012-09-29 2020-06-23 北京三星通信技术研究有限公司 一种支持对家用基站进行验证的方法
CA2983236A1 (en) 2015-04-23 2016-10-27 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
CN107158011A (zh) * 2017-05-25 2017-09-15 浙江大学 低聚半乳糖在制备治疗肠道疾病的药物中的用途
BR112021022447A2 (pt) * 2019-05-15 2021-12-28 Nutricia Nv Métodos para aumentar a função da barreira intestinal e/ou para a prevenção e/ou o tratamento de ruptura da barreira intestinal, método para o tratamento, a prevenção e/ou o alívio de uma condição associado à exposição a toxinas, fórmula infantil, fórmula de seguimento ou fórmula para criança de primeira infância, trissacarídeos, composições nutricionais, uso do trissacarídeo e usos de uma composição nutricional
US20240277739A1 (en) * 2021-07-01 2024-08-22 N.V. Nutricia Nutritonal compositions for gut barrier function
KR102453998B1 (ko) * 2022-01-07 2022-10-14 (주)네오크레마 갈락토올리고당을 포함하는 염증성 장질환의 예방, 개선 또는 치료용 조성물
GB2619977A (en) * 2022-06-24 2023-12-27 Clasado Res Services Limited Compositions and uses thereof
GB2623336A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof
GB2623335A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
GB0315266D0 (en) * 2003-06-30 2003-08-06 Clasado Inc Novel galactooligosaccharide composition and the preparation thereof
EP1644482B2 (en) * 2003-06-30 2014-10-01 Clasado Inc. Novel galactooligosaccharide composition and the preparation thereof
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
EP1887017A1 (en) * 2006-08-09 2008-02-13 Friesland Brands B.V. Prebiotic carbohydrate
GB0809921D0 (en) * 2008-05-30 2008-07-09 Clasado Inc Product and process therefor

Also Published As

Publication number Publication date
EP2421541A1 (en) 2012-02-29
HUE040451T2 (hu) 2019-03-28
GB2482817B (en) 2014-02-26
KR20110138416A (ko) 2011-12-27
RU2530567C2 (ru) 2014-10-10
NZ595969A (en) 2013-03-28
WO2010122344A1 (en) 2010-10-28
PT2421541T (pt) 2018-10-15
CY1120597T1 (el) 2019-12-11
CA2759442C (en) 2016-01-19
CA2759442A1 (en) 2010-10-28
SG175313A1 (en) 2011-11-28
GB201120030D0 (en) 2012-01-04
TR201810868T4 (tr) 2018-08-27
IL215855A0 (en) 2012-01-31
MY151104A (en) 2014-04-15
EP2421541B1 (en) 2018-07-11
ZA201107821B (en) 2012-07-25
AU2010240642A1 (en) 2011-11-10
PL2421541T3 (pl) 2018-11-30
CN102427818A (zh) 2012-04-25
GB0920784D0 (en) 2010-01-13
AU2010240642B2 (en) 2013-03-14
GB2482817A (en) 2012-02-15
JP2012524770A (ja) 2012-10-18
MX341308B (es) 2016-08-12
DK2421541T3 (en) 2018-09-24
UA106491C2 (uk) 2014-09-10
BRPI1015091A2 (pt) 2016-04-26
GB0906983D0 (en) 2009-06-03
US20120058972A1 (en) 2012-03-08
RU2011147390A (ru) 2013-05-27
MX2011011159A (es) 2011-11-07

Similar Documents

Publication Publication Date Title
ES2688786T3 (es) Nuevo uso
Dunleavy et al. Intestinal barrier dysfunction in inflammatory bowel disease: underpinning pathogenesis and therapeutics
US20110082102A1 (en) Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation
US11040021B2 (en) Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
Wu et al. Butyrolactone-I, an efficient α-glucosidase inhibitor, improves type 2 diabetes with potent TNF-α–lowering properties through modulating gut microbiota in db/db mice
Rui-Zhi et al. Astragalus mongholicus Bunge and Panax Notoginseng formula (A&P) combined with Bifidobacterium contribute a renoprotective effect in chronic kidney disease through inhibiting macrophage inflammatory response in kidney and intestine
RU2410100C2 (ru) Фармацевтическая композиция ингибитора протонной помпы и пребиотика для лечения язвенных поражений желудка и 12-перстной кишки
Zheng et al. Sodium houttuyfonate alleviates post-infarct remodeling in rats via AMP-activated protein kinase pathway
Tian et al. Galacto-oligosaccharides alleviate LPS-induced immune imbalance in small intestine through regulating gut microbe composition and bile acid pool
Wu et al. Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease
Shimoyama et al. Study of the mechanisms of a J apanese traditional fermented medicine in the improvement of constipation
El-Sayyad Future impact of probiotic therapy of metabolic disorder
JP2008538098A (ja) ボンベシン／ガストリン放出ペプチドアンタゴニストの、炎症性状態、急性肺損傷及び双極性障害の治療のための使用
Maldonado Galdeano et al. Malnutrition: role of the diet on the microbiota and in the functioning of the gut immune system
Angelova Intestinal Epithelial and Immune Host Receptors in Giardiasis
Spence et al. Digestive Disease Week 2020
Ganguly et al. Gut Microbiota in Type 2 Diabetes
Xie et al. Yanggan Yizhong decoction prevents liver metastasis from colorectal cancer by targeting myeloid-derived suppressor cells through the regulation of bile acid metabolism in the gut microbiota
Manchanayake The Impact of Gut Microbiota on Host Obesity. J Gastrointest Dig Syst 9: 591. doi: 10.4172/2161-069X. 1000591 Page 2 of 8 J Gastrointest Dig Syst, an open access journal ISSN: 2161-069X Volume 9• Issue 1• 1000591
He et al. W2006 Beneficial Effects of Fermented Milk Containing Lactobacillus GG and L. Gasseri Tmc0356 On Regulating Intestinal Microflora and Immune Responses for Patients with Allergic Disease
Doherty et al. W2011 Meta-Analysis of Probiotics in the Prevention of Post-Operative Recurrence of Crohn's Disease
Petitta et al. OC. 05.6: ANTIOXIDANTS RESTORE PERSISTENT LIPOPOLYSACCHARIDE (LPS)-INDUCED ALTERATIONS IN HUMAN COLONIC SMOOTH MUSCLE